OPTICROM Drug Patent Profile

Which patents cover Opticrom, and what generic alternatives are available?

Opticrom is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in OPTICROM is cromolyn sodium. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cromolyn sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Opticrom

A generic version of OPTICROM was approved as cromolyn sodium by SANDOZ on June 16^th, 1999.

Summary for OPTICROM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	98
Patent Applications:	4,783
DailyMed Link:	OPTICROM at DailyMed

US Patents and Regulatory Information for OPTICROM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984		DISCN	Yes	No

Expired US Patents for OPTICROM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	4,053,628
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	3,419,578
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	3,975,536
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	3,777,033
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	3,686,412

International Patents for OPTICROM

See the table below for patents covering OPTICROM around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1920365
Australia	465305
Germany	1918142
Ireland	36337	PHARMACEUTICAL COMPOSITIONS
Switzerland	481912	Procédé de préparation de dérivés de la chromone à activité pharmaceutique

OPTICROM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for OPTICROM (Cromolyn Sodium)

Introduction to OPTICROM

OPTICROM, a brand name for the generic drug cromolyn sodium, is an ophthalmic medication used to treat allergic conjunctivitis and other eye allergies. Understanding the market dynamics and financial trajectory of OPTICROM is crucial for stakeholders, including pharmaceutical companies, investors, and healthcare providers.

Market Size and Growth

The global market for cromolyn sodium, including OPTICROM, is part of the broader ophthalmic drugs market. This market is expected to see significant growth due to increasing demand for effective treatments for eye-related disorders.

• The ophthalmic drugs market is projected to grow from USD 34.64 billion in 2024 to USD 51.46 billion by 2029, at a CAGR of 8.24%[1].
• While specific figures for OPTICROM are not isolated, the overall growth in the ophthalmic drugs market indicates a positive outlook for cromolyn sodium-based products.

Regional Dynamics

North America: A Key Market

North America, particularly the United States, is a significant market for ophthalmic drugs, including OPTICROM.

• North America leads the global ophthalmic drugs market, driven by a highly developed healthcare infrastructure, strong market presence, and favorable reimbursement policies[1].
• The U.S. ophthalmic drugs market alone was estimated at USD 15.53 billion in 2023 and is anticipated to grow at a CAGR of 7.4% from 2024 to 2030[4].

Asia-Pacific: Emerging Market

The Asia-Pacific region is also experiencing rapid growth in the ophthalmic drugs market, driven by increasing consumer awareness and a rising burden of ophthalmic disorders.

• This region is expected to be one of the fastest-growing markets for ophthalmic drugs, including cromolyn sodium-based products like OPTICROM[1].

Market Catalysts

Several factors drive the market for OPTICROM and similar ophthalmic drugs:

Increasing Prevalence of Eye-Related Disorders

• The rising prevalence of eye-related disorders, such as allergic conjunctivitis, is a significant driver. For instance, over 50 million Americans aged 18 and above reported vision loss, with many experiencing significant vision issues[4].

Technological Advancements

• Innovations in drug delivery systems, including new formulations and administration methods, are enhancing the efficacy and patient compliance of ophthalmic drugs like OPTICROM[1].

Regulatory and Reimbursement Environment

• Favorable reimbursement policies and a supportive regulatory environment in regions like North America encourage the development and use of ophthalmic drugs[1].

Financial Trajectory

Cost Savings

• Including cromolyn sodium in treatment plans can lead to significant cost savings. For example, it has been shown to reduce the average cost of emergency room visits and hospital admissions substantially[2].

Revenue and Volume Share

• The market for cromolyn sodium is segmented by type and application, with eye drops being a significant segment. The revenue and volume share of these segments indicate a healthy financial trajectory for OPTICROM and similar products[2].

Market Forecast

• The global market for cromolyn sodium is expected to grow from 2024 to 2031, driven by increasing demand and therapeutic efficacy. This growth is attractive to investors and pharmaceutical companies[2].

Competitive Landscape

Major Players

• Companies like Allergan, which markets OPTICROM, are key players in the ophthalmic drugs market. These companies focus on expanding their product portfolios and market presence through research, innovation, and strategic collaborations[2].

Market Concentration

• The ophthalmic drugs market, including the segment for cromolyn sodium, is characterized by high market concentration. Major players dominate the market, but there is still room for innovation and entry by new competitors[1].

Technological Advancements

Improvements in Manufacturing and Drug Delivery

• Advances in manufacturing and drug delivery systems are crucial for the growth of the ophthalmic drugs market. Innovations such as gene therapies and new pharmacologic agents are pushing treatment efficacy forward[1].

Combination Therapies

• The trend towards combination therapies and unique action mechanisms further diversifies ophthalmic care solutions, including those involving cromolyn sodium[1].

Key Takeaways

• Growing Demand: The demand for cromolyn sodium, including OPTICROM, is increasing due to its therapeutic efficacy and cost-effectiveness.
• Market Segmentation: The market is segmented by type and application, with eye drops being a significant segment.
• Cost Savings: Including cromolyn sodium in treatment plans can lead to significant cost savings.
• Technological Advancements: Improvements in manufacturing and drug delivery systems are crucial for market growth.
• Competitive Landscape: Major manufacturers are focusing on expanding their product portfolios and market presence.

FAQs

What is OPTICROM used for?

OPTICROM, a brand name for cromolyn sodium, is used to treat allergic conjunctivitis and other eye allergies.

What is the expected growth rate of the ophthalmic drugs market?

The ophthalmic drugs market is expected to grow at a CAGR of 8.24% from 2024 to 2029[1].

How does cromolyn sodium impact healthcare costs?

Cromolyn sodium can significantly reduce healthcare costs by lowering the average cost of emergency room visits and hospital admissions[2].

Which region is leading the ophthalmic drugs market?

North America leads the global ophthalmic drugs market, driven by a highly developed healthcare infrastructure and favorable reimbursement policies[1].

What are the key drivers of the ophthalmic drugs market?

Key drivers include the increasing prevalence of eye-related disorders, technological advancements in drug development, and favorable regulatory and reimbursement environments[1].

Sources

1. Mordor Intelligence: Ophthalmic Drugs Market Size Research - Industry Trends & Share
2. Drug Patent Watch: Cromolyn sodium - Generic Drug Details
3. PharmiWeb: Ophthalmic Drugs Market Dynamics Propel Growth to USD 85.6 Billion
4. Grand View Research: U.S. Ophthalmic Drugs Market Size | Industry Report, 2030
5. STADA: Annual Report 2023 | STADA